Stockscreener 앱 받기
8.0303
1.01%
0.0803
전일 마감가:
$7.95
열려 있는:
$7.96
하루 거래량:
2,555
Relative Volume:
0.47
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.24%
1개월 성능:
-9.20%
6개월 성능:
-46.46%
1년 성능:
-53.85%
1일 변동 폭
$7.96
$8.06
1주일 범위:
$7.66
$8.06
52주 변동 폭
$7.66
$18.20
Advisorshares Psychedelics Etf Stock (PSIL) Company Profile
Advisorshares Psychedelics Etf 주식(PSIL)의 최신 뉴스
(PSIL) Trading Signals - Stock Traders Daily
Reverse split for AdvisorShares Psychedelic ETF starts today - Green Market Report
AdvisorShares Announces Reverse Split of ETF - PR Newswire
PSILAdvisorShares Psychedelics ETF Latest Stock News & Market Updates - StockTitan
Cannabis And Psychedelics Industries: Summer's Over, Where Are We? - Benzinga
AdvisorShares Psychedelics ETF (NYSEARCA:PSIL) Trading Down 1% - Defense World
VIXY Jumped 7.3% Last Week - Yahoo Finance
Best Psychedelic ETFs - Benzinga
Time for Healthcare ETFs? - Yahoo Finance
Top and Flop ETFs of the First Half - Zacks Investment Research
How to Invest in the Semiconductor Value Chain with These ETFs - The Globe and Mail
Advisorshares Psychedelics ETF (PSIL-A) QuotePress Release - The Globe and Mail
TD Asset Management: The Future of Quantitative Investing - The Globe and Mail
Best and Worst ETF Zones of Q2 - Zacks Investment Research
AdvisorShares Psychedelics ETF (NYSEARCA:PSIL) Trading 0.9% Higher - Defense World
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment - Markets Insider
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment - Benzinga
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD TreatmentATAI Life Sciences (NASDAQ - Benzinga
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment - Benzinga
AdvisorShares Psychedelics ETF (NYSEARCA:PSIL) Stock Holdings Increased by Spire Wealth Management - Defense World
Investors Warm Up to Psychedelics as FDA Reviews Treatment for PTSD - BNN Bloomberg
ETF Issuer: Bristol Gate Capital Partners Inc. - The Globe and Mail
The Impact of Bitcoin Halving on Investors and ETFs to Explore - The Globe and Mail
A New Horizon: Horizons ETF Management Canada to rebrand as Global X - The Globe and Mail
LSD, Ecstasy Lure Traders Betting on ‘Psychedelic Renaissance’ - Bloomberg
Mental Health Mavericks: 3 Stocks Changing the Game - Yahoo Finance
Viridian Capital finds psychedelic stocks typically trade at 3x book - Green Market Report
Psychedelic Funding & Public Markets in 2023 - Psychedelic Alpha
11 Most Promising Psychedelic Stocks According to Hedge Funds - Yahoo Finance
MAPS PBC submits first-ever NDA for MDMA-assisted PTSD therapy - Proactive Investors UK
New Report Predicts Psychedelic Industry Shakeout - Green Market Report
Will Psychedelics Companies Win The Mental Health Boom? - Finimize
How to Invest in Psychedelics - Investing News Network
'We’re in the shakeout stage': The psychedelics boom in healthcare has lost its buzz as some companies struggle to make payroll - Fortune
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More - Benzinga
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More - Benzinga
AdvisorShares' Noah Hamman: "It Could Be a Rough, Rough Year" - Nasdaq
PSIL: When Investing In Psychedelic Firms, ETFs Are The Safer Route (NYSEARCA:PSIL) - Seeking Alpha
Options Listed for the AdvisorShares MSOS 2x Daily ETF (Ticker: MSOX) - PR Newswire
The 7 Most Promising Psychedelic Stocks to Buy in February - InvestorPlace
Psychedelics in the Public Markets: 2022 - Psychedelic Alpha
Worst Performing ETFs of 2022 - etf.com
Math Over Myth: Positive Technical Divergences in the Psychedelic Sector - Psychedelic Spotlight
Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3 - Psychedelic Spotlight
Psychedelic Stocks: ARK Invest and the Reverse Midas Touch - Psychedelic Spotlight
7 Psychedelics Stocks to Buy for a Big Drug Boom - Yahoo Finance
AdvisorShares Expands Cannabis ETF Offerings, Launches MSOS 2x Daily ETF (Ticker: MSOX) - PR Newswire
The Growth Potential Of Psychedelics Stocks And ETFs - Seeking Alpha
The Four Psychedelics ETFs Capturing Investor Attention - Psychedelic Spotlight
Understanding 3 Risks of Investing in Psychedelic Stocks - Psychedelic Spotlight
Best & Worst Performing ETFs Of 2022 - Yahoo Finance
Advisorshares Psychedelics Etf (PSIL) 재무 분석
Advisorshares Psychedelics Etf (PSIL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.78%
0.51%
자본화:
|
볼륨(24시간):